NCT05715853 (PARK) is a clinical trial of QSant in Kidney Transplant Failure and Rejection, sponsored by NephroSant.

Who is sponsoring NCT05715853?

NCT05715853 is sponsored by NephroSant.

What drugs are being tested in NCT05715853?

Interventions in NCT05715853: QSant.

What condition does NCT05715853 study?

NCT05715853 studies Kidney Transplant Failure and Rejection.

Is NCT05715853 still recruiting?

NCT05715853 is currently status unknown. Last updated 8 February 2023.

Last reviewed 2023-02-08 · How we verify

NCT05715853: PARK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Assessment of Rejection in Kidney Transplant (PARK)

Status unknown Last updated 8 February 2023

What this trial tests

trial testing QSant in Kidney Transplant Failure and Rejection in 1,000 participants. Status unknown.

Timeline

20 December 2022

Primary endpoint
30 September 2023

30 September 2023

Quick facts

Lead sponsor	NephroSant
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	20 December 2022
Primary completion	30 September 2023
Estimated completion	30 September 2023
Sites	1 location across United States

Drugs / interventions tested

QSant

Conditions studied

Kidney Transplant Failure and Rejection — all drugs for Kidney Transplant Failure and Rejection →

Sponsor

NephroSant

Who can join

18 and older, any sex, with Kidney Transplant Failure and Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PARK study is a multi-center observational study to assess the performance of the QSant test with kidney biopsy. QSant is a test based on 6 urinary biomarkers that is used for the evaluation and management of acute rejection in renal allograft recipients with clinical suspicion of rejection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Transplant Failure and Rejection

Currently open trials in the same condition.

NCT05325008 — A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients · Phase 3 · recruiting
NCT03955172 — Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated · NA · recruiting
NCT04526431 — Tacrolimus Pharmacokinetic Subpopulations · recruiting
NCT04369612 — Home Based Monitoring of Kidney Transplants Utilizing Capillary Microsamples · NA · recruiting
NCT03380962 — Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant · Phase 1, PHASE2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05715853 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by NephroSant
Last refreshed: 8 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05715853.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing